How GLP-1 medicines work in the body

The hormone came first

GLP‑1 stands for glucagon-like peptide‑1. It is a hormone your own gut has released after every meal of your life, from L‑cells in the lower small intestine and colon, in response to food arriving.

It is one of the incretins — hormones that explain a curiosity noticed decades ago, that glucose taken by mouth produces far more insulin than the same glucose given intravenously. The gut, it turned out, tells the pancreas that food is coming.

Four things it does

• Prompts insulin release, but only when glucose is high. This is the part that matters most clinically. GLP‑1's effect on the beta cell is glucose-dependent: when blood sugar is normal, it does little. That is why these medicines carry a low risk of hypoglycaemia on their own, unlike insulin or the sulfonylureas.
• Suppresses glucagon. Glucagon is insulin's opposite number and tells the liver to release stored glucose. Turning it down after a meal lowers the glucose the liver adds on top of the meal itself.
• Slows gastric emptying. Food leaves the stomach more gradually, so glucose arrives in a lower, flatter wave. This is also the direct cause of the nausea and early fullness people report.
• Acts on the brain. There are GLP‑1 receptors in the hypothalamus and brainstem, in the circuits that govern appetite and satiety. This is where the weight effect largely comes from.

Why appetite, not willpower

The most consistent thing people describe is not that eating became harder. It is that food stopped occupying their attention — what is sometimes called food noise. The background negotiation goes quiet.

That is a direct consequence of the fourth mechanism. Appetite is regulated by hormones acting on a specific set of neurons, and those neurons are what the medicine reaches. Describing the result as willpower is a category error that has been made about obesity for a century.

What the medicines actually change

Native GLP‑1 is destroyed within about two minutes by an enzyme called DPP‑4. That is useless as a medicine.

The analogues solve this in two ways: small changes to the amino acid sequence so the enzyme no longer recognises it, and a fatty acid chain that binds the molecule to albumin in the blood, releasing it slowly. Together these take a two-minute hormone to a half-life of around a week, which is why semaglutide is injected once weekly rather than constantly.

So the medicines do not introduce a foreign mechanism. They extend one that was already there.

Not all of them are the same molecule

Liraglutide is a daily GLP‑1 analogue. Semaglutide is a weekly one. Tirzepatide is different again: it activates both the GLP‑1 receptor and the GIP receptor, GIP being the other major incretin, and its effects on weight in trials have been larger. A single-receptor and a dual-receptor medicine are not interchangeable, and which is appropriate is a clinical decision.

What follows from the mechanism

Two things follow directly, and both are predictable rather than surprising.

The gastrointestinal side effects — nausea, fullness, constipation — come from slowed gastric emptying, which is why doses are escalated gradually rather than started at the target.

And because the appetite effect depends on continued receptor activation, appetite returns when the medicine stops. This is the mechanism behaving exactly as described, not a failure of the treatment or the person.

A note on scope

This explains biology. Whether a GLP‑1 medicine is appropriate for any individual depends on their measurements, their history and their other medicines, and that assessment belongs to a physician.